The following trials provide information to treat various types of disease of the brain and the central and local nervous systems, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1446 in Male and Non-fertile Female, young and Elderly Healthy Volunteers, After Oral Multiple Ascending Doses
- collapse A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 including an Open Food Effect Panel in Healthy Male and Non-fertile Female Volunteers
- collapse Open label Positron Emission Tomography (PET) study with [11C]AZD2995 and [11C]AZD2184, candidate PET ligands for ß amyloid, to determine and compare in vivo brain uptake and distribution in healthy volunteers and patients with Alzheimer’s Disease
- collapse A Phase IIa randomised, double-blind, placebo controlled, parallel group, multicentre study evaluating the efficacy, safety, tolerability and pharmacokinetics of AZD1386 after 3 weeks of treatment in patients with Posttraumatic Neuralgia (PTN) and Postherpetic Neuralgia (PHN)
- collapse A Randomised, Double-Blind, Placebo-Controlled, Single-Centre Study to Determine the Effect of Intradermal AZD3161 on Quantitative Sensory Testing Variables in Normal and UVC Exposed Skin in Healthy Volunteers
- collapse An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers with Different CYP2D6 Genotype
- collapse An Open Label, Single Dose, Phase I Study to Evaluate the Excretion of Radioactivity, the Metabolic Profile, Pharmacokinetics, Safety and Tolerability Following Single Oral Administration of [14C]AZD2423 to Healthy Male Volunteers
- collapse A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 weeks of Treatment in Adult Non-Users and users of Nicotine Containing Products
- collapse Explorative trial of AZD3480 - ADHD
- collapse Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
